# US 2024/0199589 A1 · Glp-1r modulating compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199589 A1
- Document ID: US20240199589A1
- Status: Published application
- Kind: A1
- Application number: 18/496,137
- Filed: 2023-10-27
- Published: 2024-06-20
- Earliest claimed: 2021-04-21
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Megan K. Armstrong; James S. Cassidy; Elbert Chin; Chienhung Chou; Jeromy J. Cottell; Chao-I Hung; Kavoos Kolahdouzan; David W. Lin; Michael L. Mitchell; Ezra Roberts; Scott D. Schroeder; Nathan D. Shapiro; James G. Taylor; Rhiannon Thomas-Tran; Nathan E. Wright; Zheng-Yu Yang
- Web page: https://patentgrep.com/patent/US20240199589A1

## CPC

- C07D 405/14: containing three or more hetero rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/497: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07D 401/08: linked by a carbon chain containing alicyclic rings
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 471/08: Bridged systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 493/04: Ortho-condensed systems
- C07D 493/08: Bridged systems
- C07D 493/10: Spiro-condensed systems
- C07F 9/65586: {at least one of the hetero rings does not contain nitrogen as ring hetero atom}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein
R1 is
i) C6-10 aryl or 6-membered heteroaryl, each of which is optionally substituted with one to four R4; or
ii) 6-membered heteroaryl, wherein the heteroaryl is fused to a 5- or 6-membered ring having zero to three heteroatoms, each independently N, O, or S, to form a fused ring system, wherein the fused ring system is optionally substituted with one to four R5;
ring A is
which are each optionally substituted with one to three RA, each RA independently C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, halogen, —OH, —CN, or —N(R10a)(R10b);
ring B is
(i) C6-10 aryl or heteroaryl, which is each optionally substituted with one to four RB, each RB independently C1-9 alkyl, C1-8 haloalkyl, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —NO2, —CN, —N3, —O—R10a, —C(O)R10a, —C(O)O— R10a, —N(R10a)(R10b), N(R10a)2(R10b)+, —N(R10a)C(O)—R10b, —N(R10a)C(O)O—R10b, —N(R10a)C(O)N(R10b)(R10c), —N(R10a)S(O)2(R10b), —N R10aS(O)2N(R10b)(R10c), —N R10aS(O)2O(R10b), —OC(O) R10a, —OC(O)O R10a, —OC(O)—N(R10a)(R10b), —S—R10a, —S(O) R10a, —S(O)(NH) R10a, —S(O)2 R10a, —S(O)2N(R10a)(R10b), —S(O)(N R10a) R10b, or —Si(R10a)3; or
(ii) C6-10 aryl or heteroaryl, which is each fused to a 5 or 6 membered ring having zero to four heteroatoms, each independently N, O, or S, to form a fused ring system, wherein the fused ring system is optionally substituted with one to five RB, each RB independently C1-9 alkyl, C1-8 haloalkyl, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —NO2, —CN, —N3, —O—R10a, —C(O)R10a, —C(O)O—R10a, —N(R10a)(R10b), N(R10a)2(R10b)+, —N(R10a)C(O)—R10b, —N(R10a)C(O)O—R10b, —N(R10a)C(O)N(R10b)(R10c), —N(R10a)S(O)2(R10b), —N R10aS(O)2N(R10b)(R10c), —N R10aS(O)2O(R10b), —OC(O) R10a, —OC(O)O R10a, —OC(O)—N(R10a)(R10b), —S—R10a, —S(O) R10a, —S(O)(NH) R10a, —S(O)2 R10a, —S(O)2N(R10a)(R10b), —S(O)(N R10a) R10b, or —Si(R10a)3;
V is —C(R11a)(R11b)—;
X1, X2, and X3 are each independently —C(H)═, or —C(R8)═;
R2 is
i) C3-10 cycloalkyl or heterocyclyl, wherein the cycloalkyl or heterocyclyl is each optionally substituted with one to four Z1, wherein each Z1 is independently C1-6 alkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C2-6 alkoxyalkyl, halogen, C1-6 haloalkyl, C1-6 haloalkoxy, oxo, —OH, —CN, C1-6 alkyl-CN, —C(O)R10a, —C(O)O—R10a, —C(O)NH2, —C(O)NH(C1-9 alkyl), —N(R10a)(R10b), —N(R10a)C(O)O—R10b, —N(R10a)C(O)—R10b, —S(O)2 R10a, —S(O)2(C1-9 alkyl), —O—C3-6 cycloalkyl or heteroaryl,
wherein each —O—C3-6 cycloalkyl or heteroaryl is optionally substituted with one to four Z1a groups, each Z1a independently C1-6 alkyl, C1-6 alkoxy, halogen, C1-6 haloalkyl, or C1-6 haloalkoxy; or
ii)
wherein
R2a is C1-6 alkyl, C1-6 hydroxyalkyl, C2-6 alkoxyalkyl, C1-6 haloalkyl, C1-6 alkyl-CN, —C3-6 cycloalkyl or heteroaryl,
wherein each alkyl, cycloalkyl, or heteroaryl is optionally substituted with one to four groups each independently C1-6 alkyl, C1-6 alkoxy, halogen, C1-6 haloalkyl, or C1-6 haloalkoxy;
R2b is H, C1-3 alkyl, C1-3 haloalkyl; and
R2c is H, C1-3 alkyl, C1-3 haloalkyl;
R3 is —C(O)OR3a,
wherein R3a is H, C1-4 alkyl-N(R9a)(R9b), —C1-4 alkyl-N(R9a)C(O)—O—C1-4 alkyl-OP(O)(OR9c)2, C1-4 alkyl-C(O)N(R9a)(R9b), —C1-4 alkyl-O—C(O)—C1-4 alkyl, —C1-4 alkyl-O—C(O)—O—C1-4alkyl, —C1-4 alkyl-O—C(O)—C1-4 alkyl-N(R9a)(R9b), —C1-4 alkyl-O—C(O)—C1-4 alkyl-OP(O)(OR9c)2, —CH2CH(N(R9a)2)C(O)OR9b, —P(O)(OR9c)2, —OP(O)(OR9c)2, —CH2P(O)(OR9c)2, —CH2OP(O)(OR9c)2, —OCH2P(O)(OR9c)2, C(O)OCH2P(O)(OR9c)2, —P(O)(R9c)(OR9d), —OP(O)(R9c)(OR9d), —CH2P(O)(R9c)(OR9d), —OCH2P(O)(R9c)(OR9d), —C(O)OCH2P(O)(R9c)(OR9d), —P(O)(N(R9c)2)2, —OP(O)(N(R9c)2)2, —CH2P(O)(N(R9c)2)2, —OCH2P(O)(N(R9c)2)2, —C(O)OCH2P(O)(N(R9c)2)2, —P(O)(N(R9c)2)(OR9d), —OP(O)(N(R9c)2)(OR9d), —CH2P(O)(N(R9c)2)(OR9d), —OCH2P(O)(N(R9c)2)(OR9d), —C(O)OCH2P(O)(N(R9c)2)(OR9d), —P(O)(R9c)(N(R9d)2), —OP(O)(R9c)(N(R9d)2), —CH2P(O)(R9c)(N(R9d)2), —OCH2P(O)(R9c)(N(R9d)2), —C(O)OCH2P(O)(R9c)(N(R9d)2), or C1-6 alkyl-heterocyclyl,
wherein each alkyl or heterocyclyl is optionally substituted with one to four halogens;
each R4 is independently C1-6 alkyl, C1-8 haloalkyl, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, halogen, C3-10 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —NO2, —CN, —N3, —O—R10a, —C(O)R10a, —C(O)O—R10a, —N(R10a)(R10b), —N(R10a)2(R10b)+, —N(R10a)—C(O)R10b, —N(R10a)C(O)O(R10b), —N(R10a)C(O)N(R10b)(R10c), —N(R10a)S(O)2(R10b), —N(R10a)S(O)2—N(R10b)(R10c), —N(R10a)S(O)2O(R10b), —OC(O)R10a, —OC(O)OR10a, —OC(O)—N(R10a)(R10b), —S—R10a, —S(O)R10a, —S(O)(NH)R10a, —S(O)2R10a, —S(O)2N(R10a)(R10b), —S(O)(NR10a)R10b, or —Si(R10a)3,
wherein each alkyl, haloalkyl, alkenyl or aryl is optionally substituted with one to four R5, and
wherein each cycloalkyl, heterocyclyl or heteroaryl is optionally substituted with one to four R12;
each R5 is independently C1-9 alkyl, C1-8 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —NO2, —N3, —CN, —O—R10a, —C(O)—R10a, —C(O)O—R10a, C(O)—N(R10a)(R10b), —N(R10a)(R10b), —N(R10a)2(R10b)+, —N(R10a)C(O)—R10b, —N(R10a)C(O)O—R10b, —N(R10a)C(O)N(R10b)(R10c), —N(R10a)S(O)2(R10b), —N R10aS(O)2N(R10b)(R10c), —N R10aS(O)2O(R10b), —OC(O) R10a, —OC(O)O R10a, —OC(O)—N(R10a)(R10b), —S—R10a, —S(O) R10a, —S(O)(NH) R10a, —S(O)2 R10a, —S(O)2N(R10a)(R10b), —S(O)(N R10a) R10b, or —Si(R10a)3,
wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one to four R6;
each R6 is independently C1-9 alkyl, C1-8 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-15 cycloalkyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —NO2, —N3, —CN, —O—R10a, —C(O)—R10a, —C(O)O—R10a, —C(O)—N(R10a)(R10b), —N(R10a)(R10b), —N(R10a)C(O)—R10b, —N(R10a)C(O)O—R10b, —N(R10a)C(O)N(R10b)(R10c), —N(R10a)S(O)2(R10b), —N R10aS(O)2N(R10b)(R10c), —N R10aS(O)2O(R10b), —OC(O) R10a, —OC(O)O R10a, —OC(O)—N(R10a)(R10b), —S—R10a, —S(O) R10a, —S(O)(NH) R10a, —S(O)2 R10a, —S(O)2N(R10a)(R10b), —S(O)(N R10a) R10b, or —Si(R10a)3,
wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one to four R7;
each R7 and R8 is independently C1-9 alkyl, C1-6 alkoxy, C2-6 alkoxyalkyl, C1-8 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, halogen, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, heteroaryl, oxo, —OH, —CN, —NO2, —NH2, —N3, —SH, —O(C1-9 alkyl), —O(C1-8 haloalkyl), —O(C2-6 alkenyl), —O(C2-6 alkynyl), —O(C3-15 cycloalkyl), —O(heterocyclyl), —O(C6-10 aryl), —O(heteroaryl), —NH(C1-9 alkyl), —NH(C1-8 haloalkyl), —NH(C2-6 alkenyl), —NH(C2-6 alkynyl), —NH(C3-15 cycloalkyl), —NH(heterocyclyl), —NH(C6-10 aryl), —NH(heteroaryl), —N(C1-9 alkyl)2, —N(C1-8 haloalkyl)2, —N(C2-6 alkenyl)2, —N(C2-6 alkynyl)2, —N(C3-15 cycloalkyl)2, —N(heterocyclyl)2, —N(C6-10 aryl)2, —N(heteroaryl)2, —N(C1-9 alkyl)(C1-8 haloalkyl), —N(C1-9 alkyl)(C2-6 alkenyl), —N(C1-9 alkyl)(C2-6 alkynyl), —N(C1-9 alkyl)(C3-15 cycloalkyl), —N(C1-9 alkyl)(heterocyclyl), —N(C1-9 alkyl)(C6-10 aryl), —N(C1-9 alkyl)(heteroaryl), —C(O)(C1-9 alkyl), —C(O)(C1-8 haloalkyl), —C(O)(C2-6 alkenyl), —C(O)(C2-6 alkynyl), —C(O)(C3-15 cycloalkyl), —C(O)(heterocyclyl), —C(O)(C6-10 aryl), —C(O)(heteroaryl), —C(O)O(C1-9 alkyl), —C(O)O(C1-8 haloalkyl), —C(O)O(C2-6 alkenyl), —C(O)O(C2-6 alkynyl), —C(O)O(C3-15 cycloalkyl), —C(O)O(heterocyclyl), —C(O)O(C6-10 aryl), —C(O)O(heteroaryl), —C(O)NH2, —C(O)NH(C1-9 alkyl), —C(O)NH(C1-8 haloalkyl), —C(O)NH(C2-6 alkenyl), —C(O)NH(C2-6 alkynyl), —C(O)NH(C3-15 cycloalkyl), —C(O)NH(heterocyclyl), —C(O)NH(C6-10 aryl), —C(O)NH(heteroaryl), —C(O)N(C1-9 alkyl)2, —C(O)N(C1-8 haloalkyl)2, —C(O)N(C2-6 alkenyl)2, —C(O)N(C2-6 alkynyl)2, —C(O)N(C3-15 cycloalkyl)2, —C(O)N(heterocyclyl)2, —C(O)N(C6-10 aryl)2, —C(O)N(heteroaryl)2, —NHC(O)(C1-9 alkyl), —NHC(O)(C1-8 haloalkyl), —NHC(O)(C2-6 alkenyl), —NHC(O)(C2-6 alkynyl), —NHC(O)(C3-15 cycloalkyl), —NHC(O)(heterocyclyl), —NHC(O)(C6-10 aryl), —NHC(O)(heteroaryl), —NHC(O)O(C1-9 alkyl), —NHC(O)O(C1-8 haloalkyl), —NHC(O)O(C2-6 alkenyl), —NHC(O)O(C2-6 alkynyl), —NHC(O)O(C3-15 cycloalkyl), —NHC(O)O(heterocyclyl), —NHC(O)O(C6-10 aryl), —NHC(O)O(heteroaryl), —NHC(O)NH(C1-9 alkyl), —NHC(O)NH(C1-8 haloalkyl), —NHC(O)NH(C2-6 alkenyl), —NHC(O)NH(C2-6 alkynyl), —NHC(O)NH(C3-15 cycloalkyl), —NHC(O)NH(heterocyclyl), —NHC(O)NH(C6-10 aryl), —NHC(O)NH(heteroaryl), —NHS(O)(C1-9 alkyl), —N(C1-9 alkyl)(S(O)(C1-9 alkyl), —S(C1-9 alkyl), —S(C1-8 haloalkyl), —S(C2-6 alkenyl), —S(C2-6 alkynyl), —S(C3-15 cycloalkyl), —S(heterocyclyl), —S(C6-10 aryl), —S(heteroaryl), —S(O)N(C1-9 alkyl)2, —S(O)(C1-9 alkyl), —S(O)(C1-8 haloalkyl), —S(O)(C2-6 alkenyl), —S(O)(C2-6 alkynyl), —S(O)(C3-15 cycloalkyl), —S(O)(heterocyclyl), —S(O)(C6-10 aryl), —S(O)(heteroaryl), —S(O)2(C1-9 alkyl), —S(O)2(C1-8 haloalkyl), —S(O)2(C2-6 alkenyl), —S(O)2(C2-6 alkynyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(heterocyclyl), —S(O)2(C6-10 aryl), —S(O)2(heteroaryl), —S(O)(NH)(C1-9 alkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2,
wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one to three C1-9 alkyl, C1-8 haloalkyl, halogen, —OH, —NH2, CO2H, —O(C1-9 alkyl), —O(C1-8 haloalkyl), —O(C3-15 cycloalkyl), —O(heterocyclyl), —O(aryl), —O(heteroaryl), —NH(C1-9 alkyl), —NH(C1-8 haloalkyl), —NH(C3-15 cycloalkyl), —NH(heterocyclyl), —NH(aryl), —NH(heteroaryl), —N(C1-9 alkyl)2, —N(C3-15 cycloalkyl)2, —NHC(O)(C1-8 haloalkyl), —NHC(O)(C3-15 cycloalkyl), —NHC(O)(heterocyclyl), —NHC(O)(aryl), —NHC(O)(heteroaryl), —NHC(O)O(C1-9 alkyl), —NHC(O)O(C1-8 haloalkyl), —NHC(O)O(C2-6 alkynyl), —NHC(O)O(C3-15 cycloalkyl), —NHC(O)O(heterocyclyl), —NHC(O)O(aryl), —NHC(O)O(heteroaryl), —NHC(O)NH(C1-9 alkyl), S(O)2(C1-9 alkyl), —S(O)2(C1-8 haloalkyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(heterocyclyl), —S(O)2(aryl), —S(O)2(heteroaryl), —S(O)(NH)(C1-9 alkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2,
wherein each alkyl or heterocyclyl is optionally substituted with one to four halogens;
each R9a and R9b is independently H, C1-6 alkyl, or C1-6 haloalkyl, or R9a and R9b together form a 6-membered heterocyclyl;
each R9c, R9d, R10a, R10b, and R10c is independently H, C1-9 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-15 cycloalkyl, heterocyclyl, C6-10 aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is each optionally substituted with one to four R6;
each R11a and R11b is independently —H, C1-6 alkyl, oxo, or halogen;
each R12 is C1-9 alkyl, C1-8 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, oxo, —OH, —CN, —NO2, —NH2, —N3, —SH, —O(C1-9 alkyl), —O(C1-8 haloalkyl), —O(C2-6 alkenyl), —O(C2-6 alkynyl), —O(C3-15 cycloalkyl), —O(heterocyclyl), —O(C6-10 aryl), —O(heteroaryl), —NH(C1-9 alkyl), —NH(C1-8 haloalkyl), —NH(C2-6 alkenyl), —NH(C2-6 alkynyl), —NH(C3-15 cycloalkyl), —NH(heterocyclyl), —NH(C6-10 aryl), —NH(heteroaryl), —N(C1-9 alkyl)2, —N(C1-8 haloalkyl)2, —N(C2-6 alkenyl)2, —N(C2-6 alkynyl)2, —N(C3-15 cycloalkyl)2, —N(heterocyclyl)2, —N(C6-10 aryl)2, —N(heteroaryl)2, —N(C1-9 alkyl)(C1-8 haloalkyl), —N(C1-9 alkyl)(C2-6 alkenyl), —N(C1-9 alkyl)(C2-6 alkynyl), —N(C1-9 alkyl)(C3-15 cycloalkyl), —N(C1-9 alkyl)(heterocyclyl), —N(C1-9 alkyl)(C6-10 aryl), —N(C1-9 alkyl)(heteroaryl), —C(O)(C1-9 alkyl), —C(O)(C1-8 haloalkyl), —C(O)(C2-6 alkenyl), —C(O)(C2-6 alkynyl), —C(O)(C3-15 cycloalkyl), —C(O)(heterocyclyl), —C(O)(C6-10 aryl), —C(O)(heteroaryl), —C(O)O(C1-9 alkyl), —C(O)O(C1-8 haloalkyl), —C(O)O(C2-6 alkenyl), —C(O)O(C2-6 alkynyl), —C(O)O(C3-15 cycloalkyl), —C(O)O(heterocyclyl), —C(O)O(C6-10 aryl), —C(O)O(heteroaryl), —C(O)NH2, —C(O)NH(C1-9 alkyl), —C(O)NH(C1-8 haloalkyl), —C(O)NH(C2-6 alkenyl), —C(O)NH(C2-6 alkynyl), —C(O)NH(C3-15 cycloalkyl), —C(O)NH(heterocyclyl), —C(O)NH(C6-10 aryl), —C(O)NH(heteroaryl), —C(O)N(C1-9 alkyl)2, —C(O)N(C1-8 haloalkyl)2, —C(O)N(C2-6 alkenyl)2, —C(O)N(C2-6 alkynyl)2, —C(O)N(C3-15 cycloalkyl)2, —C(O)N(heterocyclyl)2, —C(O)N(C6-10 aryl)2, —C(O)N(heteroaryl)2, —NHC(O)(C1-9 alkyl), —NHC(O)(C1-8 haloalkyl), —NHC(O)(C2-6 alkenyl), —NHC(O)(C2-6 alkynyl), —NHC(O)(C3-15 cycloalkyl), —NHC(O)(heterocyclyl), —NHC(O)(C6-10 aryl), —NHC(O)(heteroaryl), —NHC(O)O(C1-9 alkyl), —NHC(O)O(C1-8 haloalkyl), —NHC(O)O(C2-6 alkenyl), —NHC(O)O(C2-6 alkynyl), —NHC(O)O(C3-15 cycloalkyl), —NHC(O)O(heterocyclyl), —NHC(O)O(C6-10 aryl), —NHC(O)O(heteroaryl), —NHC(O)NH(C1-9 alkyl), —NHC(O)NH(C1-8 haloalkyl), —NHC(O)NH(C2-6 alkenyl), —NHC(O)NH(C2-6 alkynyl), —NHC(O)NH(C3-15 cycloalkyl), —NHC(O)NH(heterocyclyl), —NHC(O)NH(C6-10 aryl), —NHC(O)NH(heteroaryl), —NHS(O)(C1-9 alkyl), —N(C1-9 alkyl)(S(O)(C1-9 alkyl), —S(C1-9 alkyl), —S(C1-8 haloalkyl), —S(C2-6 alkenyl), —S(C2-6 alkynyl), —S(C3-15 cycloalkyl), —S(heterocyclyl), —S(C6-10 aryl), —S(heteroaryl), —S(O)N(C1-9 alkyl)2, —S(O)(C1-9 alkyl), —S(O)(C1-8 haloalkyl), —S(O)(C2-6 alkenyl), —S(O)(C2-6 alkynyl), —S(O)(C3-15 cycloalkyl), —S(O)(heterocyclyl), —S(O)(C6-10 aryl), —S(O)(heteroaryl), —S(O)2(C1-9 alkyl), —S(O)2(C1-8 haloalkyl), —S(O)2(C2-6 alkenyl), —S(O)2(C2-6 alkynyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(heterocyclyl), —S(O)2(C6-10 aryl), —S(O)2(heteroaryl), —S(O)(NH)(C1-9 alkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2,
wherein each alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one to three C1-9 alkyl, C1-8 haloalkyl, halogen, —OH, —NH2, CO2H, —O(C1-9 alkyl), —O(C1-8 haloalkyl), —O(C3-15 cycloalkyl), —O(heterocyclyl), —O(aryl), —O(heteroaryl), —NH(C1-9 alkyl), —NH(C1-8 haloalkyl), —NH(C3-15 cycloalkyl), —NH(heterocyclyl), —NH(aryl), —NH(heteroaryl), —N(C1-9 alkyl)2, —N(C3-15 cycloalkyl)2, —NHC(O)(C1-8 haloalkyl), —NHC(O)(C3-15 cycloalkyl), —NHC(O)(heterocyclyl), —NHC(O)(aryl), —NHC(O)(heteroaryl), —NHC(O)O(C1-9 alkyl), —NHC(O)O(C1-8 haloalkyl), —NHC(O)O(C2-6 alkynyl), —NHC(O)O(C3-15 cycloalkyl), —NHC(O)O(heterocyclyl), —NHC(O)O(aryl), —NHC(O)O(heteroaryl), —NHC(O)NH(C1-9 alkyl), S(O)2(C1-9 alkyl), —S(O)2(C1-8 haloalkyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(heterocyclyl), —S(O)2(aryl), —S(O)2(heteroaryl), —S(O)(NH)(C1-9 alkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2,
wherein each alkyl or heterocyclyl is optionally substituted with one to four halogens;
wherein each heterocyclyl has three to twelve ring members and has one to four heteroatoms, each independently N, O, or S; and
wherein each heteroaryl has five to twelve ring members and one to four heteroatoms, each independently N, O, or S.

### Claim at position 2

-37. (canceled)

### Claim 38 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 39 (depends on 38)

The pharmaceutical composition of claim 38 further comprising one or more additional therapeutic agents.

### Claim 40

(canceled)

### Claim 41 (depends on 1)

A method of treating GLP-1R mediated disease or condition comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 41)

The method of claim 41, wherein the disease or condition comprises a liver disease.

### Claim 43 (depends on 42)

The method of claim 42, wherein the disease or condition comprises liver fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, compensated liver fibrosis, decompensated liver fibrosis, hepatocellular carcinoma, Primary Biliary Cirrhosis (PBC), or Primary Sclerosing Cholangitis (PSC).

### Claim 44 (depends on 43)

The method of claim 43, wherein the disease or condition comprises non-alcoholic fatty liver disease (NAFLD).

### Claim 45 (depends on 43)

The method of claim 43, wherein the disease or condition comprises non-alcoholic steatohepatitis (NASH).

### Claim 46 (depends on 41)

The method of claim 41, wherein the disease or condition comprises a metabolic disease.

### Claim 47 (depends on 41)

The method of claim 41, wherein the disease or condition comprises type I diabetes, type II diabetes, pre-diabetes, idiopathic type I diabetes, latent autoimmune diabetes, maturity onset diabetes of the young, early onset diabetes, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, obesity, eating disorders, sleep apnea, weight gain, sugar craving, dyslipidemia, hyperinsulinemia, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, left ventricular hypertrophy, Parkinson's Disease, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, angina pectoris, premenstrual syndrome, thrombosis, atherosclerosis, impaired glucose metabolism, vascular restenosis, dementia, or Alzheimer's disease.

### Claim 48 (depends on 41)

The method of claim 41, wherein the compound or pharmaceutically acceptable salt thereof is administered in combination with an additional therapeutic agent.

### Claim 49 (depends on 48)

The method of claim 48, wherein the additional therapeutic agent comprises an anti-obesity agent including but not limited to peptide YY or an analogue thereof, a neuropeptide Y receptor type 2 (NPYR2) agonist, a NPYR1 agonist, an NPYR5 antagonist, a cannabinoid receptor type 1 (CB1 R) antagonist, a lipase inhibitor (e.g., orlistat), a human proislet peptide (HIP), a melanocortin receptor 4 agonist (MC4R) (e.g., setmelanotide), a melanin concentrating hormone receptor 1 antagonist, a farnesoid X receptor (FXR) agonist (e.g., obeticholic acid), apoptotic signal-regulating kinase (ASK-1) inhibitor, zonisamide, phentermine (alone or in combination with topiramate), a norepinephrine/dopamine reuptake inhibitor (e.g., bupropion), an opioid receptor antagonist (e.g., naltrexone), a combination of norepinephrine/dopamine reuptake inhibitor and opioid receptor antagonist (e.g., a combination of bupropion and naltrexone), a GDF-15 analog, sibutramine, a cholecystokinin agonist, amylin and analogues thereof (e.g., pramlintide), leptin and analogues thereof (e.g., metroleptin), a serotonergic agent (e.g., lorcaserin), a methionine aminopeptidase 2 (MetAP2) inhibitor (e.g., beloranib or ZGN-1061), phendimetrazine, diethylpropion, benzphetamine, an SGLT2 inhibitor (e.g., empagliflozin, canagliflozin, dapagliflozin, ipragliflozin, tofogliflozin, sergliflozin etabonate, remogliflozin etabonate, or ertugliflozin), an SGLTL1 inhibitor, a dual SGLT2/SGLT1 inhibitor, a fibroblast growth factor receptor (FGFR) modulator, an AMP-activated protein kinase (AMPK) activator, biotin, a MAS receptor modulator, or a glucagon receptor agonist (alone or in combination with another GLP-1 R agonist, e.g., liraglutide, exenatide, dulaglutide, albiglutide, lixisenatide, or semaglutide), a peroxisome proliferator-activated receptor alpha (PPARα) agonist, fish oil, an acetyl-coA carboxylase (ACC) inhibitor, a TGFβ antagonist, GFRAL agonist, and/or a pharmaceutically acceptable salt thereof.

### Claim at position 15

-52. (canceled)
